A Long-term Extension of Study GNC-401 With Temelimab in Patients With Relapsing Forms of Multiple Sclerosis (RMS) Under Treatment With Rituximab
Latest Information Update: 11 Jul 2022
At a glance
- Drugs Temelimab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms ProTEct-MS Extension
- Sponsors GeNeuro
- 23 May 2022 Status changed from recruiting to discontinued.
- 21 Sep 2021 New trial record